The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

52 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
15
Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.EBI
Neogenesis
1
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.EBI
Eisai
21
Modulators of leukotriene biosynthesis and receptor activation.EBI
Abbott Laboratories
18
Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.EBI
Eisai
15
Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.EBI
Smithkline Beecham Pharmaceuticals
7
 
Synthesis and pharmacologic activity of hydroxyacetophenone-substituted benzophenone/xanthone leukotriene B4 receptor antagonistsEBI
TBA
23
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.EBI
Roche Research Center
15
The Role of Receptor Binding in Drug DiscoveryEBI
TBA
3
New Leukotriene B4 Receptor Antagonist: Leucettamine A and Related Imidazole Alkaloids from the Marine Sponge Leucetta microraphisEBI
TBA
15
 
N-aryl cinnamides: A novel class of rigid and highly potent leukotriene B4 receptor antagonistsEBI
TBA
1
 
3-Amino-1,2-benzisoxazoles: A new family of potent inhibitors of LTB4 binding to the human neutrophilsEBI
TBA
4
 
Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonistsEBI
TBA
10
 
Synthesis and in vitro profile of 7-substituted quinoline chromanols as novel, non-acidic LTB4 antagonistsEBI
TBA
8
 
2-alkyl-4-ethyl-5-[6-methyl-6-(2H-tetrazol-5-yl)heptyloxy]phenol leukotriene B4 receptor antagonistsEBI
TBA
11
 
Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivityEBI
TBA
5
 
Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist: spatial positioning of the secondary acid groupEBI
TBA
6
 
Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on in vitro and in vivo LTB4 receptor antagonismEBI
TBA
4
 
Ortho-alkoxyphenol leukotriene B4 receptor antagonists: effect of a chroman carboxylic acid.EBI
TBA
8
 
Ortho-alkoxyphenol leukotriene B4 receptor antagonistsEBI
TBA
1
 
Enantioselective total synthesis and pharmacologic profile of 12-deoxy-12(S)-methyl leukotriene B4EBI
TBA
6
Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.EBI
Bristol Myers Squibb
22
Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics.EBI
Wyeth Research
6
Leukotriene B4 photoaffinity probes: design, synthesis and evaluation of new arylazide-1,3-disubstituted cyclohexanes.EBI
Upresa-Cnrs 5074
27
Human disorders associated with inflammation and the evolving role of natural products to overcome.EBI
University of Delhi
1
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.EBI
Novartis Pharmaceuticals
10
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.EBI
Smithkline Beecham Pharmaceuticals
3
Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain.EBI
RhôNe-Poulenc Rorer
3
A novel series of [2-[methyl(2-phenethyl)amino]-2-oxoethyl] benzene-containing leukotriene B4 antagonists: initial structure-activity relationships.EBI
Rhone-Poulenc Rorer Central Research
6
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.EBI
Smithkline Beecham Pharmaceuticals
7
Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists.EBI
Eli Lilly
6
Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists.EBI
Eli Lilly
13
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.EBI
Solvay Duphar
7
Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.EBI
Smithkline Beecham Pharmaceuticals
32
Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.EBI
Smithkline Beecham Pharmaceuticals
17
Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.EBI
Eli Lilly
19
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.EBI
Smithkline Beecham Pharmaceuticals
1
(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.EBI
Pfizer
20
Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore.EBI
Searle Research and Development
5
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.EBI
Eli Lilly
1
Bis(sulfato)-cyclosiphonodictyol A, a new disulfated sesquiterpene-hydroquinone from a deep water collection of the Marine sponge Siphonodictyon coralliphagum.EBI
Harbor Branch Oceanographic Institution
1
7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8- propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist.EBI
G.D. Searle And
2
Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain.EBI
Eli Lilly
41
omega-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists.EBI
Centre De Recherche De Vitry-Alfortville
22
omega-[(4-Phenyl-2-quinolyl)oxy]alkanoic acid derivatives: a new family of potent LTB4 antagonists.EBI
Centre De Recherche De Vitry-Alfortville
4
4-[2-[Methyl(2-phenethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-2- naphthalenecarboxylic acid: a high affinity, competitive, orally active leukotriene B4 receptor antagonist.EBI
Rhone-Poulenc Rorer Central Research
22
Omega-[(omega-arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists.EBI
Centre De Recherche De Vitry-Alfortville
21
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.EBI
Merck Frosst Centre For Therapeutic Research
163
Sulfonamide compounds and uses as TNAP inhibitorsBDB
Sanford-Burnham Prebys Medical Discovery Institute
24
Prolyl hydroxylase inhibitors and methods of useBDB
Akebia Therapeutics
116
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitorsBDB
Ziarco Pharma
6
Splicing factor SF3b as a target of the antitumor natural product pladienolide.BDB
Eisai